feedback

Course Director

Richard S. Finn, MD

Geffen School of Medicine at UCLA
Los Angeles, California, USA

Accredited by

Global Education Group

Activity Details

Credit Types:CME
Credit Amount:0.5 Credits
Release Date:2020-Sep-01
Expiration Date:2021-Aug-31
Estimated Time for Completion:30 minutes
Registration Required:No
Cost:Free of Charge

Support

This activity is supported by educational grants from Eisai Inc., Genentech, a member of the Roche Group and Merck & Co., Inc.

Activity Description and Educational Objectives

In this activity, an expert in oncology discusses evolving therapeutic strategies to optimize the management of patients with unresectable hepatocellular carcinoma (HCC).

Upon completion of this activity, participants should be better able to:
  • Evaluate the clinical data supporting current and emerging first-line systemic treatment strategies for patients with unresectable HCC
  • Identify relevant factors that should be considered when selecting available and emerging systemic therapies
  • Select a personalized, evidence-supported treatment plan that balances the efficacy and safety of systemic treatments for patients with unresectable HCC

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, hepatologists, interventional radiologists, gastroenterologists, and other clinicians involved in the treatment of hepatocellular carcinoma.

Faculty Disclosure Statement / Conflict of Interest Policy

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Course Director and Faculty

Richard S. Finn, MD
Professor, Department of Medicine
Division of Hematology/Oncology
Geffen School of Medicine, University of California
Los Angeles, California, USA

Richard S. Finn, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca Plc; Bayer AG; Bristol-Myers Squibb Company; CStone Pharmaceuticals; Eisai Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Merck & Co., Inc.; and Pfizer Inc.
Grant/Research Support from Paid to UCLA: Eisai Inc.; Eli Lilly and Company; Merck & Co.; Pfizer Inc.; and Roche/Genentech, Inc.
Advisory Board for AstraZeneca Plc; Bayer AG; Bristol-Myers Squibb Company; CStone Pharmaceuticals; Eisai Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Merck & Co., Inc.; and Pfizer Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvansky; Andrea Funk; Liddy Knight; Ashley Cann have no financial interests/relationships or affiliations in relation to this activity.

Answers in CME Medical Director

Serena Welch, MD has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Answers in CME do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Answers in CME. Global is accredited by the ACCME to provide continuing medical education for physicians.

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Global Education Group Answers in CME
This CME activity is jointly provided by Global Education Group and Answers in CME. There is no fee to participate in this activity.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 80% is needed.

Media: Enduring Material
Release and Expiration Dates: September 1, 2020 - August 31, 2021
Time to Complete: 30 minutes

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Answers in CME or any of its supporters.

System Requirements

Our educational activities are available on Mac and PC.

For the best online experience, we recommend using the latest versions of these supported browsers:
Depending on your browser of choice, additional software, such as Adobe® Flash® Player and Adobe Reader may be required.

If you have any technical issues, feel free to contact us by email at info@answersincme.com.

Global Contact Information

For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

© 2018-2020, Answers in CME

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.